• Careers
  • Contact Us
  • Start a Conversation
QED Therapeutics
  • Discover
    Infigratinib
    • Targeting FGFR
    • Infigratinib
    • Pipeline
    • Clinical Trials Currently Enrolling
  • Cholangiocarcinoma
    (Bile Duct Cancer)
  • Urothelial Carcinoma
    (Bladder Cancer)
  • Achondroplasia
  • Medical
    Professionals
    • Medical Professionals
    • Investigator-Sponsored Trials (IST)
    • Independent Medical Education (IME)
    • Sponsorships
    • Expanded Access Program
  • About Us
    • About QED Therapeutics
    • Our Team
    • BridgeBio
  • Resource
    Room
  • Menu
Start a Conversation With Us
  • Sign Up to Stay Informed

    I am an HCP and would like to someone from QED to contact me.

  • Date Format: MM slash DD slash YYYY
  • :
     
  • *Required fields.

    Communication Agreement

    By completing this form and clicking the SUBMIT button, you understand and hereby consent to your personal information being stored on a database in the United States and accessible to QED Therapeutics for purposes such as marketing programs from QED Therapeutics, disseminating information about research from QED Therapeutics regarding infigratinib and related health conditions, and obtaining feedback about our products and services. You may request access to, removal, or correction of your personal information by sending an email to: medinfo@QEDTx.com. Please review the full QED Therapeutics privacy policy for more information on your rights with respect to your personal information. If you are a resident of the European Union, please note that by submitting your information to QED through this form, you are expressly consenting to transfer of your personal data to the United States.

  • This field is for validation purposes and should be left unchanged.
  • Sign Up to Stay Informed

  • *Required fields.

    Communication Agreement

    By completing this form and clicking the SUBMIT button, you understand and hereby consent to your personal information being stored on a database in the United States and accessible to QED Therapeutics for purposes such as marketing programs from QED Therapeutics, disseminating information about research from QED Therapeutics regarding infigratinib and related health conditions, and obtaining feedback about our products and services. You may request access to, removal, or correction of your personal information by sending an email to: medinfo@QEDTx.com. Please review the full QED Therapeutics privacy policy for more information on your rights with respect to your personal information. If you are a resident of the European Union, please note that by submitting your information to QED through this form, you are expressly consenting to transfer of your personal data to the United States.

  • This field is for validation purposes and should be left unchanged.

Contact Us

75 Federal Street
San Francisco, CA 94107

1-877-280-5655

Maps were disabled by the visitor on this site.

©2020 QED Therapeutics, Inc. All rights reserved. | Privacy Policy | Terms of Use | Expanded Access Policy

Scroll to top

Leaving Site

By selecting “Proceed” you will leave QEDTx.com and be directed to an external website.

Cancel Proceed